196960-96-0

Upstream product

• 5419-55-6 Triisopropyl borate 
• 14804-34-3 3-tert-butyl-4-methoxybromobenzene 
• 13780-71-7 dihydroxyborane 
• 121-43-7 Trimethyl borate 
• 10323-39-4 4-bromo-2-tert-butylphenol 

Downstream Products

• 1202392-75-3 2,7-bis(3-tert-butyl-4-methoxyphenyl)naphthalene 
• 345306-28-7 5,6-Bis(3-tert-butyl-4-hydroxyphenyl)acenaphthtene 
• 487945-12-0 1,8-bis-(3-tert-butyl-4-methoxy-phenyl)-2,7-diisopropoxy-naphthalene 
• 303764-14-9 5,6-Bis(3-tert-butyl-4-methoxyphenyl)acenaphthene 

Relevant academic research and scientific papers

Heterocyclic derivatives for the treatment of cancer and other proliferative diseases

The invention relates to certain heterocyclic compounds useful for the treatment of cancer and other diseases, having the Formula (I): wherein: (a) m is an integer 0 or 1; (b) R12 is an alkyl, a substituted alkyl, a cycloalkyl, a substituted cycloalkyl, a heterocyclic, a substituted heterocyclic, a heteroaryl, a substituted heteroaryl, an aryl or a substituted aryl residue; (c) Ar3 is an aryl, a substituted aryl, a heteroaryl or a substituted heteroaryl residue; (d) Ar4 is an aryl, a substituted aryl, a heteroaryl or a substituted heteroaryl residue; (e) R5 is hydrogen, hydroxy, alkyl or substituted alkyl; (f) - - - - - represents a bond present or absent; and (g) W, X, Y and Z are independently or together C(O)—, C(S), S, O, or NH; or a pharmaceutically acceptable salt thereof.

Attempts to find a solution to the problem of atropisomer interconversion in 1,8-diarylnaphthalenes and 5,6-diarylacenaphthenes

A series of sterically restricted 5,6-diarylacenaphthenes 5, 11, 12, 13 and 14 have been prepared via Suzuki crosscouplings of the appropriate boronic acids with 5,6-dibromoacenaphthene 3 in an attempt to prevent atropisomer interconversion in these systems. Attempts to further functionalise bis(p-methoxyphenyl) system 5 in the position ortho to the methyl ethers by Friedel-Crafts acylation or metallation were unsuccessful; however, two unexpected products were obtained, p,p′-Dimethoxybiphenyl 6 results from an unexpected rearrangement of 5 under strongly basic conditions and is dependent on the base used, whilst acylated derivative 7 results from a Friedel-Crafts acylation of the acenaphthene scaffold in the 3-position, rather than the desired functionalisation of the peri-aryl rings, presumably due to the difficulty in forming a tetrahedral intermediate. The oxygen functionality in 5 has been used, following methyl ether cleavage via diphenol 8 and allylation via 9, to demonstrate the viability of a double Claisen rearrangement yielding 11 after acetylation. However, the broad 1H NMR exhibited by 11 clearly showed that this system is not configurationally stable, hence steps were required to access more sterically demanding systems which would be configurationally stable. Molecular mechanics and semi-empirical simulations were carried out on related biaryl systems to determine if a single bulky substituent in the 3-position of the peri-aryl rings would be sufficient to prevent atropisomer interconversion. The modelling showed that the energies of the syn- and antiatropisomeric forms, e.g. for 12-14, were surprisingly similar. With the objective of preparing conformationally stable molecules in this class in mind, 12-14 were prepared in remarkable yield for such a hindered system. In spite of extensive attempts to determine whether 13 was configurationally stable, enantiomeric separation could not be achieved. Unsuccessful attempts were thus made to detect the presence of stable atropisomeric forms of 13 through the synthesis of bis(benzyl ether) 19, in which the benzylic protons could act as enantiotopic reporters. In addition mandelate ester 20 was prepared and it was shown by 1H NMR that a mixture of anti- and syn-diastereoisomers had been obtained. It was therefore concluded that steric groups in the 3-position of the peri-aryl rings cannot be used to prevent atropisomer interconversion in 1,8-diarylnaphthalenes and 5,6-diarylacenaphthenes. During attempts to access diphenols 18 and 24, other by-products were isolated, i.e. 21 and 25 respectively, resulting from a steric strain-induced 1,2-aryl shift.

Bicyclic-aromatic compounds

PCT No. PCT/FR97/00391 Sec. 371 Date Jan. 26, 1998 Sec. 102(e) Date Jan. 26, 1998 PCT Filed Mar. 5, 1997 PCT Pub. No. WO97/33881 PCT Pub. Date Sep. 18, 1997The invention relates to novel bicyclic aromatic compounds which have the general formula (I): as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.